David M. Stack - 05 Aug 2021 Form 4 Insider Report for CHIASMA, INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 05 Aug 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Aug 2021, 17:51:50 UTC
Prior SEC filing: 16 Jun 2021
Next SEC filing: 18 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Lee G. Giguere, Attorney-in-Fact

Key filing fact

David M. Stack filed Form 4 for CHIASMA, INC on 05 Aug 2021.

Key facts

This page summarizes David M. Stack's Form 4 filing for CHIASMA, INC.
8 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 05 Aug 2021, 17:51.

Change

Previous filing in this sequence was filed on 16 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CHMA transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -25,000
Change %: -100%
Price
Shares after: 0
Date: 05 Aug 2021
Ownership: See Footnote
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -91,954
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 91,954
Exercise price: $3.29
Footnotes: F1, F4

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -72,683
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 72,683
Exercise price: $5.57
Footnotes: F1, F4

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -10,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $3.14
Footnotes: F1, F4

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -13,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,000
Exercise price: $1.35
Footnotes: F1, F4

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -13,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,000
Exercise price: $1.45
Footnotes: F1, F4

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -13,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,000
Exercise price: $7.98
Footnotes: F1, F4

CHMA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -13,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,000
Exercise price: $5.81
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David M. Stack is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").

Footnote F2

At the Effective Time, each share of common stock of the Company (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.396 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing five ordinary shares of Parent.

Footnote F3

Shares held by Three Colleens Investment LLC, a limited liability company jointly owned and managed by the Reporting Person and his spouse. This Form 4 shall not be deemed an admission of beneficial ownership of these shares by the Reporting Person except to the extent of his pecuniary interest therein.

Footnote F4

At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised prior to the Effective Time, whether or not vested, by virtue of the Merger, ceased to represent a right to acquire Shares and was converted into the option to purchase Parent ADSs (each an "Assumed Stock Option"). The number of Parent ADSs shall be equal to (i) number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.